PR PolyResearch

Join Free

NASDAQ

BioXcel Therapeutics, Inc. (BTAI)

♥ 532 Thanks from members

BioXcel Therapeutics (BTAI) exhibits severe financial distress, flagged by going concern risks and low revenues, countered by clinical advancement of its lead neuropsychiatric drug candidate, BXCL501, and an upcoming PDUFA date.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)